Published in final edited form as:

Prog Lipid Res. 2008 September ; 47(5): 333–339. doi:10.1016/j.plipres.2008.03.004.

CTP synthetase and its role in phospholipid synthesis in the yeast *Saccharomyces cerevisiae*

Yu-Fang Chang and George M. Carman*

Department of Food Science and Rutgers Center for Lipid Research, Rutgers University, New Brunswick, New Jersey 08901

Abstract

CTP synthetase is a cytosolic-associated glutamine amidotransferase enzyme that catalyzes the ATP-dependent transfer of the amide nitrogen from glutamine to the C-4 position of UTP to form CTP. In the yeast *Saccharomyces cerevisiae*, the reaction product CTP is an essential precursor of all membrane phospholipids that are synthesized via the Kennedy (CDP-choline and CDP-ethanolamine branches) and CDP-diacylglycerol pathways. The *URA7* and *URA8* genes encode CTP synthetase in *S. cerevisiae*, and the *URA7* gene is responsible for the majority of CTP synthesized *in vivo*. The CTP synthetase enzymes are allosterically regulated by CTP product inhibition. Mutations that alleviate this regulation result in an elevated cellular level of CTP and an increase in phospholipid synthesis via the Kennedy pathway. The *URA7*-encoded enzyme is phosphorylated by protein kinases A and C, and these phosphorylations stimulate CTP synthetase activity and increase cellular CTP levels and the utilization of the Kennedy pathway. The *CTPS1* and *CTPS2* genes that encode human CTP synthetase enzymes are functionally expressed in *S. cerevisiae*, and rescue the lethal phenotype of the *ura7Δ ura8Δ* double mutant that lacks CTP synthetase activity. The expression in yeast has revealed that the human *CTPS1*-encoded enzyme is also phosphorylated and regulated by protein kinases A and C.

Keywords

CTP; CTP synthetase; CDP-diacylglycerol; CDP-choline; CDP-ethanolamine; phospholipid synthesis; phosphorylation

1. Introduction

CTP is an essential nucleotide that is synthesized from UTP via the reaction catalyzed by the cytosolic-associated enzyme CTP synthetase [1,2] Fig. 1. The enzyme catalyzes a complex set of reactions that include the ATP-dependent transfer of the amide nitrogen from glutamine (i.e., glutaminase reaction) to the C-4 position of UTP to generate CTP (Fig. 1). GTP stimulates the glutaminase reaction by accelerating the formation of a covalent glutaminyl enzyme intermediate [2] [3]. In the yeast *Saccharomyces cerevisiae*, CTP synthetase is an essential enzyme [4,5] that provides the CTP precursor of the CDP-based intermediates used for the synthesis of membrane phospholipids (Fig. 2). This review summarizes our current understanding of the regulation of CTP synthetase activity, and how this regulation influences

*Corresponding author, E-mail: carman@aesop.rutgers.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

the synthesis of membrane phospholipids in *S. cerevisiae*. We will also discuss how studies with yeast have facilitated a greater understanding of the regulation of human CTP synthetase.

2. The central role of CTP in the synthesis of membrane phospholipids

The CTP synthetase reaction product CTP plays an essential role in the synthesis of all membrane phospholipids in *S. cerevisiae* [6–8]. CTP is the direct precursor of the activated, energy-rich phospholipid pathway intermediates CDP-diacylglycerol [9], CDP-choline [10], and CDP-ethanolamine [10] (Fig. 2). CDP-diacylglycerol is the source of the phosphatidyl moiety of the major phospholipids phosphatidylserine, phosphatidylethanolamine, and phosphatidylcholine that is synthesized by way of the CDP-diacylglycerol pathway (shown in *red color*) as well as phosphatidylglycerol, cardiolipin, and phosphatidylinositol [6–8,11] (Fig. 2). The phosphatidylinositol derived from CDP-diacylglycerol also serves as the precursor for yeast sphingolipids [12,13], the D-3, D-4, and D-5 phosphoinositides [7,14–17], and glycosyl phosphatidylinositol anchors [18,19] (Fig. 2). CDP-choline and CDP-ethanolamine are the sources of the hydrophilic head groups of phosphatidylcholine and phosphatidylethanolamine that are synthesized by the CDP-choline and CDP-ethanolamine branches, respectively, of the Kennedy pathway [6–8,11] (Fig. 2, shown in *green color*).

3. CTP synthetases of *S. cerevisiae*

Ozier-Kalogeropoulos and coworkers [4,5] have identified two genes (i.e., *URA7* and *URA8*) that encode CTP synthetase enzymes in *S. cerevisiae*. The coding sequences of the *URA7* and *URA8* genes show 70 % identity at the nucleotide level, and their deduced amino acid sequences (i.e., Ura7p and Ura8p) show 78 % identity [4,5]. The subunit molecular masses of Ura7p and Ura8p are 64.7 and 64.5 kDa, respectively [4,5]. Neither gene is essential provided that cells possess one functional gene encoding the CTP synthetase enzyme [5]. The *URA7* mRNA is 2-fold more abundant than the *URA8* transcript [5,20,21]. In a *ura8* mutant, CTP levels are 22 % lower than in wild type, whereas the CTP concentration in a *ura7* mutant is 64 % lower than in wild-type [5]. Thus, the *URA7*-encoded CTP synthetase is responsible for the majority of the CTP made *in vivo* [5].

The *URA7*- and *URA8*-encoded CTP synthetase enzymes have been purified to homogeneity and characterized with respect to their kinetic and enzymological properties [21,22]. The purification of the enzymes has been facilitated by their overexpression in yeast on multicopy plasmids [21,22]. The purified *URA7*- and *URA8*-encoded CTP synthetases exist as dimers and they oligomerize to tetramers in the presence of the substrates UTP and ATP [21–23]. The two enzymes differ, however, with respect to their kinetic properties. The *URA7*-encoded enzyme shows positive cooperative kinetics when the UTP concentration is varied at a saturating concentration of ATP or when the ATP concentration is varied at a saturating concentration of UTP [22]. In contrast, the *URA8*-encoded CTP synthetase exhibits positive cooperative kinetics when the UTP concentration is varied at subsaturating concentrations of ATP or when the ATP concentration is varied at subsaturating concentrations of UTP [21]. The cellular concentrations of UTP (0.75 mM) and ATP (2.3 mM) are considered to be saturating for both the *URA7*- and *URA8*-encoded enzymes [4,22]. Under these conditions, the *URA8*-encoded CTP synthetase would be expected to exhibit saturation kinetics toward UTP and ATP, and the *URA7*-encoded CTP synthetase would be expected to show positive cooperativity toward the substrates. Thus, it is possible that the activities of both enzymes may be regulated differentially *in vivo* through the cellular concentrations of UTP and ATP [21].

CTP synthetase enzymes have been isolated from both prokaryotic and eukaryotic organisms [2,21,22,24–27]. Moreover, structures for the bacterial [28,29] and human [30] enzymes have been solved. The yeast CTP synthetases have high homology to bacterial and mammalian CTP synthetase enzymes [28–32]. All CTP synthetases identified from bacteria, parasites, yeast and

mammals contain conserved CTP synthetase and glutamine amide transfer domains that are involved in catalysis (Fig. 3) [28–30,33–39]. The analysis of the *Escherichia coli* structure has shown that CTP synthetase has a novel product inhibition mechanism in which shared substrate and product moieties bind to a single subsite while specificity is conferred by separate sites [34]. The enzymological and kinetic properties of the enzyme from various organisms are similar, although some differences have been noted [25,27].

4. CTP regulates CTP synthetase activity and the synthesis of membrane phospholipids

The *URA7*- and *URA8*-encoded CTP synthetase enzymes are allosterically inhibited by the product CTP [21,22]. This regulation ultimately determines the intracellular concentration of CTP [20,22]. CTP inhibits the CTP synthetase activity by increasing the positive cooperativity of the enzyme for UTP, and at the same time, decreasing the affinity (as reflected in an increase in K_m) for UTP [21,22]. This inhibition mechanism is also true for the CTP synthetases from *E. coli* [2] and rat liver [26]. Because CTP and UTP have distinct binding sites on CTP synthetase [32,40], it is likely that CTP does not compete with UTP for the active site.

CTP synthetase mutants defective in CTP product inhibition have been isolated from Chinese hamster ovary cells [41]. The mutants were selected for their resistance to the growth inhibitory effects of the chemotherapeutic drugs arabinosyl cytosine and 5-fluorouracil [41]. Sequence analysis of the CTP synthetase gene from these mutants has revealed that most of the mutations are clustered within a stretch of 14 amino acids [41]. The most frequent mutations in the clustered region of the enzyme are glutamate-to-lysine and histidine-to-lysine changes [41]. The clustered sites are in a highly conserved region of the CTP synthetases from human cells [42], *E. coli* [31], *Chlamydia trachomatis* [43], *Bacillus subtilis* [44], and *S. cerevisiae* [4,5]. These amino acids correspond to Glu¹⁶¹ and His²³³ in the *URA7*- and *URA8*-encoded CTP synthetases. The codons for Glu¹⁶¹ and His²³³ in the *URA7* and *URA8* genes have been changed to lysine codons individually or in combination by site-directed mutagenesis, and the effect of these mutations on the balance of pyrimidine nucleotide pools in cells have been examined [45]. Between the two mutations, E161K showed a more significant effect on CTP synthetase activity when compared with the H233K mutation [45]. The *URA7*- and *URA8*-encoded CTP synthetases containing the E161K mutation are less sensitive to CTP product inhibition and are resistant to growth inhibition of cyclopentenylcytosine [45], another drug used for cancer chemotherapy [46–49]. Consequently, cells expressing the E161K mutant enzymes have greater intracellular level (6- to 15-fold) of CTP when compared with cells that express the wild type forms of the enzyme [45].

In addition to elevated CTP levels, cells expressing the E161K mutation show alterations in the synthesis of membrane phospholipids [45]. These cells exhibit an increase in the synthesis of phosphatidylcholine, phosphatidylethanolamine, and phosphatidate, and a decrease in the synthesis of phosphatidylserine [45]. The increase in phosphatidylcholine synthesis has been ascribed to an increase in the utilization of the CDP-choline branch of the Kennedy pathway [45] (Fig. 2). The increased utilization of the Kennedy pathway in response to elevated CTP levels has been attributed to the stimulation of phosphocholine cytidyltransferase activity, the enzyme that catalyzes the rate-limiting penultimate step in the Kennedy pathway (Fig. 1) [20]. The stimulation of this activity is simply due to increased substrate availability of CTP [20,50]. In wild type cells, the apparent K_m of CTP (1.4 mM) for the phosphocholine cytidyltransferase [51] is 2-fold higher than the cellular concentration of CTP (0.7 mM) [20]. Thus, the activity of the cytidyltransferase enzyme would be sensitive to the elevation of cellular CTP levels [20]. Indeed, the overexpression of CTP synthetase activity results in an increase in the cellular concentration of CDP-choline [20,50]. Likewise, the K_m of CTP (1 mM) for the CDP-diacylglycerol synthase [52] is higher than the cellular concentration of CTP

in wild type cells, and the overexpression of CTP synthetase activity results in an increase in the cellular concentration of CDP-diacylglycerol [20]. However, this does not result in a greater utilization of the CDP-diacylglycerol pathway for phosphatidylcholine synthesis [20]. In contrast to the phosphocholine cytidyltransferase reaction, the synthesis of CDP-diacylglycerol is not a rate-limiting step in the CDP-diacylglycerol pathway [53]. Moreover, phosphatidylserine synthase, a key enzyme in the CDP-diacylglycerol pathway, is inhibited by CTP [20]. Thus, the inhibition of a CDP-diacylglycerol pathway enzyme favors the synthesis of phospholipids by the Kennedy pathway. Indeed, the CDP-diacylglycerol and Kennedy pathways compensate for each other to maintain phospholipid composition [8,54].

Other consequences of the misregulation of CTP synthetase by CTP product inhibition (i.e., E161K mutation) include a 1.6-fold increase in the ratio of neutral lipids to phospholipids [45]. The increase in neutral lipids is due to increased levels of triacylglycerols (1.4-fold), free fatty acids (1.7-fold), and ergosterol esters (1.8-fold) [45]. The mechanism(s) for these changes have not been addressed, but may be related to the increase in phosphatidate concentration that occurs in response to elevated levels of CTP [45]. Recent studies have shown that phosphatidate plays a central role in the transcriptional regulation of lipid synthesis in *S. cerevisiae* [11]. Indeed, cells that express the E161K mutation excrete inositol [45], a characteristic phenotype that typifies the misregulation of phospholipid synthetic genes when cells accumulate an excess of phosphatidate [11]. The increase in phosphatidate might be due to an increase in phospholipase D activity and/or due to activation of another enzyme(s) that generate this phospholipid.

5. Regulation of CTP synthetase by phosphorylation

Phosphorylation is a posttranslational modification by which various cellular enzymes and transcription factors are regulated [55,56]. Phosphorylation may stimulate or inhibit the function of an enzyme or transcription factor [57,58]. It may also regulate the oligomerization of enzymes and transcription factors and control protein stability [59]. The localization and/or translocation of some enzymes and transcription factors are also controlled by phosphorylation [59–65]. The *S. cerevisiae* *URA7*-encoded CTP synthetase is phosphorylated by protein kinase A and by protein kinase C. Protein kinase A is cyclic-AMP dependent protein kinase that mediates signals through the Ras-cAMP pathway [66,67]. Protein kinase C is a lipid-dependent protein kinase required for *S. cerevisiae* cell cycle [68–72] and plays a role maintaining cell wall integrity [73]. The phosphorylation of purified *URA7*-encoded CTP synthetase by protein kinase A and protein kinase C results in the stimulation of enzyme activity by 190 % and 300 %, respectively [74,75]. *In vivo* labeling studies have shown that the phosphorylation of CTP synthetase by protein kinase A [74] and protein kinase C [75] is physiologically relevant. The stimulation of CTP synthetase by protein kinases A or C may be related to signal transduction pathways that direct the cell growth, proliferation, and biosynthesis of macromolecules. Kinetic analyses show that the mechanisms for stimulation of CTP synthetase activity by the two different protein kinases are the same [74,75]. Phosphorylated CTP synthetase shows an increase in the $V_{\max}$ with respect to the substrates UTP and ATP, a decrease in the K_m value toward ATP, and a decrease in the positive cooperativity of the enzyme for ATP [74,75]. Moreover, the phosphorylation of CTP synthetase by protein kinases A and C attenuates the regulation of its activity by CTP product inhibition [74,75].

The effects of phosphorylation on the regulation of *URA7*-encoded CTP synthetase activity involve the oligomerization of the enzyme [22,23]. CTP synthetase exists as a dimer in the absence of its substrates ATP and UTP, but in the presence of saturating concentrations of these substrates the enzyme exists as a tetramer [22,23] (Fig. 4). The kinetics of enzyme tetramerization correlates with the kinetics of enzyme activity. The product CTP does not inhibit the ATP/UTP-dependent tetramerization of the enzyme [22,23]. Phosphorylation of

native CTP synthetase with protein kinases A and C facilitates the nucleotide-dependent tetramerization, whereas dephosphorylation of native CTP synthetase with alkaline phosphatase prevents its nucleotide-dependent tetramerization [23]. This correlates with the inactivation of CTP synthetase activity [23]. The rephosphorylation of the enzyme with protein kinases A and C results in a partial restoration of the nucleotide-dependent tetramerization of the enzyme, and this correlates with the partial restoration of CTP synthetase activity [23] (Fig. 4).

A combination of biochemical and molecular approaches has been used to identify protein kinase A and protein kinase C sites in the *URA7*-encoded CTP synthetase [76–78]. Ser⁴²⁴ is a target site for both protein kinase A and protein kinase C [76,78]. The phosphorylation of this site is required to maintain optimum CTP synthetase activity *in vivo* [76,78]. Protein kinase C also phosphorylates Ser³⁶, Ser³³⁰, Ser³⁵⁴, and Ser⁴⁵⁴ [77]. Biochemical and physiological analyses of Ser-to-Ala mutations have shown that phosphorylations at all sites, with the exception of Ser³³⁰, result in the stimulation of CTP synthetase activity [77,78]. The phosphorylation of Ser³³⁰ results in the inhibition of activity [77]. Moreover, *in vivo* studies using these mutants have shown that the regulatory effects of the phosphorylations at specific sites have an impact on the pathways by which membrane phospholipids are synthesized. Phosphorylations at Ser³⁶, Ser³⁵⁴, and Ser⁴⁵⁴ correlate with an increase in PC synthesis via the Kennedy pathway [77,78]. In contrast, phosphorylation at Ser³³⁰ correlates with a decrease in the utilization of the Kennedy pathway [77].

6. *S. cerevisiae* is a surrogate to study the regulation of human CTP synthetase

The yeast expression system, like bacterial systems, facilitates the isolation of proteins for structure-function studies. However, the yeast expression system has the advantage over bacterial systems in that the effects of posttranslational modifications (e.g., phosphorylation) on human enzymes can be evaluated. The human and *S. cerevisiae* CTP synthetase enzymes have a relatively high degree of amino acid sequence identity (~53%). Indeed, the human CTP synthetase genes (i.e., *CTPS1* and *CTPS2*) are functionally expressed in *S. cerevisiae* [79]. Moreover, the *CTPS1* or *CTPS2* genes rescue the lethal phenotype of the *S. cerevisiae* *ura7Δ ura8Δ* double mutant that lacks CTP synthetase activity [79].

In vivo labeling experiments with *S. cerevisiae* cells have revealed that the human *CTPS1*-encoded CTP synthetase is phosphorylated [79]. Moreover, the extent of enzyme phosphorylation nearly doubles when yeast cells are activated for the Ras-cAMP pathway and protein kinase A activity [79] and when cells are activated for protein kinase C activity [80]. Indeed, the human CTP synthetase expressed and purified from *S. cerevisiae* *ura7Δ ura8Δ* cells is phosphorylated by mammalian forms of protein kinase A [81] and protein kinase C [80]. Biochemical and molecular studies have shown that Thr⁴⁵⁵ is a major target site of both protein kinase A and protein kinase C phosphorylation [80,81]. Likewise, Ser⁴⁶² has been identified as a major target site for protein kinase C [80]. Results of *in vitro* and *in vivo* analyses of T455A and S462A mutant CTP synthetase 1 enzymes support the conclusion that phosphorylation at Thr⁴⁵⁵ results in the inhibition of CTP synthetase 1 activity while phosphorylation at Ser⁴⁶² stimulates activity [80,81]. When expressed in *S. cerevisiae*, the T455A mutation in the human enzyme causes a 2.5-fold increase in the cellular concentration of CTP and a 1.5-fold increase in the choline-dependent synthesis of phosphatidylcholine [81]. The effects of the S462A mutation of the human enzyme on phospholipid synthesis in *S. cerevisiae* have not been examined. Protein kinase A and protein kinase C phosphorylate human CTP synthetase 1 on additional serine and threonine residues, but the identification of those sites has not been determined.

Interestingly, the direct effect of protein kinase A phosphorylation on human CTP synthetase 1 activity is opposite to that of the *S. cerevisiae* *URA7*-encoded CTP synthetase [74,76]. As discussed above, the yeast enzyme is phosphorylated on Ser⁴²⁴, and this phosphorylation results in the stimulation of CTP synthetase activity [76]. The protein kinase A phosphorylation sites in the *S. cerevisiae* (i.e., Ser⁴²⁴) and the human (i.e., Thr⁴⁵⁵) CTP synthetases are not conserved. The opposing effects of the phosphorylation of these sites could reflect differences in the regulatory functions of protein kinase A in these organisms. In *S. cerevisiae*, the activation of Ras and the subsequent elevation in protein kinase A activity by cAMP production are associated with rapid cell growth and enhanced metabolic activity of the cell [66,67,82]. The stimulation of yeast CTP synthetase activity by protein kinase A phosphorylation might provide a mechanism by which the Ras-cAMP pathway mediates the synthesis of the CTP required for yeast cell growth. In contrast, cAMP levels and protein kinase A activity are not controlled through the Ras pathway in mammalian cells, and the roles of protein kinase A activity in cell physiology are much more complex than in *S. cerevisiae* [56]. The inhibition of CTP synthetase 1 activity in response to protein kinase A phosphorylation may be a mechanism by which CTP synthesis and cell growth are attenuated in specific tissues/organs in humans. Indeed, the protein kinase A and protein kinase C phosphorylations of CTP synthetase 1 are not detected in human embryonic kidney 293 cells [83]. In this cell type, the major protein kinase that phosphorylates CTP synthetase 1 is glycogen synthase 3, and this phosphorylation inhibits CTP synthetase activity [83].

7. Summary and Perspectives

In this review, we have summarized our current understanding of CTP synthetase in *S. cerevisiae*. The *URA7*-encoded CTP synthetase is responsible for the majority of CTP synthesized *in vivo*, and the enzyme is regulated on a biochemical level by CTP product inhibition and by phosphorylations via protein kinases A and C. These forms of regulation govern the cellular levels of CTP, which in turn influence the utilization of the Kennedy and CDP-diacylglycerol pathways of phospholipid synthesis. The *URA8*-encoded enzyme is also regulated by CTP product inhibition and contains putative phosphorylation sites. We speculate that phosphorylation also regulates the *URA8*-encoded enzyme, and that this modification has effects on cellular functions that depend on CTP.

Studies with the yeast CTP synthetases have spurred studies on the human forms of the enzyme. The expression of human CTP synthetase enzymes in a yeast mutant that lacks CTP synthetase has facilitated structure-function analysis of protein kinase A and protein kinase C target sites. While the CTP synthetase enzymes from yeast and human cells are similar, there are differences with respect to the sites of phosphorylation, and the effects of phosphorylation on CTP synthetase activity. Comparison of their structures might shed light on the molecular basis for these differences.

Aside from being an essential precursor for membrane phospholipid synthesis, CTP is a precursor for the synthesis of RNA, DNA, and sialoglycoproteins [55,84,85]. In mammalian systems, CTP synthetase mutations that alleviate CTP product inhibition result in abnormally high intracellular levels of CTP and dCTP [45,86,87], resistance to nucleotide analog drugs used in cancer chemotherapy [88–91], and increased rates of spontaneous mutations [48,89, 91]. As discussed above, CTP synthetase activity controls the balance of nucleotide pools [4, 5,22,45,48,86,92] and regulates the pathways by which phospholipids are synthesized [20, 45,93]. The importance of understanding the regulation of CTP synthetase is further emphasized by the fact that elevated/unregulated CTP levels are characteristic of many forms of cancer [48,86,93–103]. Accordingly, CTP synthetase is a target for cancer therapy. In addition, the enzyme is a target for treating human diseases (e.g., African sleeping sickness [27,104], malaria [105,106], blindness [107]) that are caused by parasites. CTP synthetase

inhibitors such as cyclopentenylcytosine [108,109] and 3-deazauridine [110,111] that are currently available are not entirely specific. Based on the importance of phosphorylation in the regulation of CTP synthetase activity, novel inhibitors may be discovered and/or designed that are based on key phosphorylation sites in the enzyme. There are still numerous phosphorylation sites in the human CTP synthetase enzymes that have yet to be characterized, and clearly, additional studies toward this end are warranted. The expression of human CTP synthetase enzymes in *S. cerevisiae* would facilitate the evaluation of inhibitors that control cellular CTP levels.

Acknowledgments

This review is dedicated to the Carman laboratory members who have worked on the yeast and human CTP synthetase enzymes. This review would not be possible without their hard work and dedication. We also thank Gil-Soo Han for the critical reading of this manuscript. This work was supported in part by United States Public Health Service Grant GM-50679 from the National Institutes of Health.

References

1. Liberman I. Enzymatic amination of uridine triphosphate to cytidine triphosphate. *J.Biol.Chem* 1956;222:765–775. [PubMed: 13367044]
2. Long CW, Pardee AB. Cytidine triphosphate synthetase of *Escherichia coli* B. Purification and kinetics. *J.Biol.Chem* 1967;242:4715–4721. [PubMed: 4862983]
3. Levitzki A, Koshland, DE Jr. Role of an allosteric effector. Guanosine triphosphate activation in cytosine triphosphate synthetase. *Biochemistry* 1972;11:241–246. [PubMed: 4550559]
4. Ozier-Kalogeropoulos O, Fasiolo F, Adeline M-T, Collin J, Lacroute F. Cloning, sequencing and characterization of the *Saccharomyces cerevisiae* URA7 gene encoding CTP synthetase. *Mol.Gen.Genet* 1991;231:7–16. [PubMed: 1753946]
5. Ozier-Kalogeropoulos O, Adeline M-T, Yang W-L, Carman GM, Lacroute F. Use of synthetic lethal mutants to clone and characterize a novel CTP synthetase gene in *Saccharomyces cerevisiae*. *Mol.Gen.Genet* 1994;242:431–439. [PubMed: 8121398]
6. Carman GM, Henry SA. Phospholipid biosynthesis in yeast. *Annu.Rev.Biochem* 1989;58:635–669. [PubMed: 2673019]
7. Paltauf, F.; Kohlwein, SD.; Henry, SA. Regulation and compartmentalization of lipid synthesis in yeast. In: Jones, EW.; Pringle, JR.; Broach, JR., editors. *The Molecular and Cellular Biology of the Yeast Saccharomyces: Gene Expression*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1992. p. 415-500.
8. Carman GM, Henry SA. Phospholipid biosynthesis in the yeast *Saccharomyces cerevisiae* and interrelationship with other metabolic processes. *Prog.Lipid Res* 1999;38:361–399. [PubMed: 10793889]
9. Carter JR, Kennedy EP. Enzymatic synthesis of cytidine diphosphate diglyceride. *J.Lipid Res* 1966;7:678–683. [PubMed: 4291255]
10. Kennedy EP, Weiss SB. The function of cytidine coenzyme in the biosynthesis of phospholipids. *J.Biol.Chem* 1956;222:193–214. [PubMed: 13366993]
11. Carman GM, Henry SA. Phosphatidic acid plays a central role in the transcriptional regulation of glycerophospholipid synthesis in *Saccharomyces cerevisiae*. *J.Biol.Chem* 2007;282:37293–37297. [PubMed: 17981800]
12. Dickson RC. Sphingolipid functions in *Saccharomyces cerevisiae*: Comparison to mammals. *Annu.Rev.Biochem* 1998;67:27–48. [PubMed: 9759481]
13. Dickson RC, Lester RL. Sphingolipid functions in *Saccharomyces cerevisiae*. *Biochim.Biophys.Acta* 2002;1583:13–25. [PubMed: 12069845]
14. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. *Annu.Rev.Biochem* 1998;67:481–507. [PubMed: 9759495]
15. Balla T. Phosphatidylinositol 4-kinases. *Biochim.Biophys.Acta* 1998;1436:69–85. [PubMed: 9838049]

16. Gehrman T, Heilmayer LG Jr. Phosphatidylinositol 4-kinases. *Eur.J.Biochem* 1998;253:357–370. [PubMed: 9654085]
17. Odorizzi G, Babst M, Emr SD. Phosphoinositide signaling and the regulation of membrane trafficking in yeast. *Trends Biochem.Sci* 2000;25:229–235. [PubMed: 10782093]
18. Leidich SD, Drapp DA, Orlean P. A conditionally lethal yeast mutant blocked at the first step in glycosyl phosphatidylinositol anchor synthesis. *J Biol.Chem* 1994;269:10193–10196. [PubMed: 8144596]
19. Leidich SD, Orlean P. Gpi1, a *Saccharomyces cerevisiae* protein that participates in the first step in glycosylphosphatidylinositol anchor synthesis. *J Biol.Chem* 1996;271:27829–27837. [PubMed: 8910381]
20. McDonough VM, Buxeda RJ, Bruno MEC, Ozier-Kalogeropoulos O, Adeline M-T, McMaster CR, Bell RM, Carman GM. Regulation of phospholipid biosynthesis in *Saccharomyces cerevisiae* by CTP. *J.Biol.Chem* 1995;270:18774–18780. [PubMed: 7642527]
21. Nadkarni AK, McDonough VM, Yang W-L, Stuke JE, Ozier-Kalogeropoulos O, Carman GM. Differential Biochemical Regulation of the *URA7*- and *URA8*-encoded CTP synthetases from *Saccharomyces cerevisiae*. *J.Biol.Chem* 1995;270:24982–24988. [PubMed: 7559626]
22. Yang W-L, McDonough VM, Ozier-Kalogeropoulos O, Adeline M-T, Flocco MT, Carman GM. Purification and characterization of CTP synthetase, product of the *URA7* gene in *Saccharomyces cerevisiae*. *Biochemistry* 1994;33:10785–10793. [PubMed: 8075080]
23. Pappas A, Yang W-L, Park T-S, Carman GM. Nucleotide-dependent Tetramerization of CTP Synthetase from *Saccharomyces cerevisiae*. *J.Biol.Chem* 1998;273:15954–15960. [PubMed: 9632643]
24. Anderson PM. CTP synthetase from *Escherichia coli*: An improved purification procedure and characterization of hysteretic and enzyme concentration effects on kinetic properties. *Biochemistry* 1983;22:3285–3292. [PubMed: 6349684]
25. Wadskov-Hansen SL, Willemoes M, Martinussen J, Hammer K, Neuhaed J, Larsen S. Cloning and verification of the *Lactococcus lactis* pyrG gene and characterization of the gene product, CTP synthase. *J.Biol.Chem* 2001;276:38002–38009. [PubMed: 11500486]
26. Thomas PE, Lamb BJ, Chu EHY. Purification of cytidine-triphosphate synthetase from rat liver, and demonstration of monomer, dimer and tetramer. *Biochim.Biophys.Acta* 1988;953:334–344. [PubMed: 3355843]
27. Fijolek A, Hofer A, Thelander L. Expression, purification, characterization and in vivo targeting of trypanosome CTP synthetase for treatment of African sleeping sickness. *J Biol.Chem* 2007;282in press.
28. Endrizzi JA, Kim H, Anderson PM, Baldwin EP. Crystal structure of *Escherichia coli* cytidine triphosphate synthetase, a nucleotide-regulated glutamine amidotransferase/ATP-dependent amidoligase fusion protein and homologue of anticancer and antiparasitic drug targets. *Biochemistry* 2004;43:6447–6463. [PubMed: 15157079]
29. Goto M, Omi R, Nakagawa N, Miyahara I, Hirotsu K. Crystal structures of CTP synthetase reveal ATP, UTP, and glutamine binding sites. *Structure.(Camb.)* 2004;12:1413–1423. [PubMed: 15296735]
30. Kursula P, Flodin S, Ehn M, Hammarstrom M, Schuler H, Nordlund P, Stenmark P. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. *Acta Crystallograph.Sect.F.Struct.Biol.Cryst.Commun* 2006;62:613–617.
31. Weng M, Makaroff CA, Zalkin H. Nucleotide sequence of *Escherichia coli* pyrG encoding CTP synthetase. *J.Biol.Chem* 1986;261:5568–5574. [PubMed: 3514618]
32. McPartand RP, Weinfield H. Cytidine 5'triphosphate synthetase of calf liver. *J.Biol.Chem* 1976;251:4372–4378. [PubMed: 932036]
33. Lim RLH, O'Sullivan WJ, Stewart TS. Isolation, characterization and expression of the gene encoding cytidine triphosphate synthetase from *Giardia intestinalis*. *Mol.Biochem.Parasitol* 1996;78:249–257. [PubMed: 8813694]
34. Endrizzi JA, Kim H, Anderson PM, Baldwin EP. Mechanisms of product feedback regulation and drug resistance in cytidine triphosphate synthetases from the structure of a CTP-inhibited complex. *Biochemistry* 2005;44:13491–13499. [PubMed: 16216072]

35. Willemoes M, Molgaard A, Johansson E, Martinussen J. Lid L11 of the glutamine amidotransferase domain of CTP synthase mediates allosteric GTP activation of glutaminase activity. *FEBS J* 2005;272:856–864. [PubMed: 15670165]
36. Willemoes M, Sigurskjold BW. Steady-state kinetics of the glutaminase reaction of CTP synthase from *Lactococcus lactis*. The role of the allosteric activator GTP incoupling between glutamine hydrolysis and CTP synthesis. *Eur.J.Biochem* 2002;269:4772–4779. [PubMed: 12354108]
37. Willemoes M. Thr-431 and Arg-433 Are Part of a Conserved Sequence Motif of the Glutamine Amidotransferase Domain of CTP Synthases and Are Involved in GTP Activation of the *Lactococcus lactis* Enzyme. *J.Biol.Chem* 2003;278:9407–9411. [PubMed: 12522217]
38. Zalkin H. CTP synthetase. *Methods Enzymol* 1985;113:282–287. [PubMed: 3911002]
39. Iyengar A, Bearne SL. Aspartate-107 and leucine-109 facilitate efficient coupling of glutamine hydrolysis to CTP synthesis by *Escherichia coli* CTP synthase. *Biochem.J* 2003;369:497–507. [PubMed: 12383057]
40. McPartland RP, Weinfeld H. Cooperative effects of CTP on calf liver CTP synthetase. *J.Biol.Chem* 1979;254:11394–11398. [PubMed: 500649]
41. Whelan J, Phear G, Yamauchi M, Meuth M. Clustered base substitutions in CTP synthetase conferring drug resistance in chinese hamster ovary cells. *Nature Genetics* 1993;3:317–321. [PubMed: 7981751]
42. Yamauchi M, Yamauchi N, Meuth M. Molecular cloning of the human CTP synthetase gene by functional complementation with purified human metaphase chromosomes. *EMBO J* 1990;9:2095–2099. [PubMed: 2113467]
43. Tipples G, McClarty G. Cloning and expression of the *Chlamydia trachomatis* gene for CTP synthetase. *J.Biol.Chem* 1995;270:7908–7914. [PubMed: 7713886]
44. Trach K, Chapman JW, Piggot P, Lecoq D, Hoch JA. Complete sequence and transcriptional analysis of the *spoOF* region of the *Bacillus subtilis* chromosome. *J.Bacteriol* 1988;170:4194–4208. [PubMed: 2457578]
45. Ostrander DB, O'Brien DJ, Gorman JA, Carman GM. Effect of CTP synthetase regulation by CTP on phospholipid synthesis in *Saccharomyces cerevisiae*. *J.Biol.Chem* 1998;273:18992–19001. [PubMed: 9668079]
46. Zhang H, Cooney DA, Zhang MH, Ahluwalia G, Ford H Jr, Johns DG. Resistance to cyclopentenylcytosine in murine leukemia L1210 cells. *Cancer Res* 1993;53:5714–5720. [PubMed: 7694793]
47. Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim H-Y, Marquez VE, Johns DG. Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. *J.Biol.Chem* 1989;264:713–718. [PubMed: 2910861]
48. Meuth M, L'Heureux-Huard N, Trudel M. Characterization of a mutator gene in chinese hamster ovary cells. *Proc.Nat.Acad.Sci.USA* 1979;76:6505–6509. [PubMed: 293738]
49. de Saint Vincent BR, Buttin G. Studies on 1- β -D-arabinofuranosylcytosine-resistant mutants of chinese hamster fibroblasts. *Biochim.Biophys.Acta* 1980;610:352–359.
50. Kent C, Carman GM. Interactions of pathways for phosphatidylcholine metabolism, CTP synthesis, and secretion through the Golgi apparatus. *Trends Biochem.Sci* 1999;24:146–150. [PubMed: 10322420]
51. Nikawa J, Yonemura K, Yamashita S. Yeast mutant with thermolabile CDP-choline synthesis: Isolation and characterization of a cholinephosphate cytidyltransferase mutant. *Eur.J.Biochem* 1983;131:223–229. [PubMed: 6299731]
52. Kelley MJ, Carman GM. Purification and characterization of CDPdiacylglycerol synthase from *Saccharomyces cerevisiae*. *J.Biol.Chem* 1987;262:14563–14570. [PubMed: 2822695]
53. Kelley MJ, Bailis AM, Henry SA, Carman GM. Regulation of phospholipids biosynthesis in *Saccharomyces cerevisiae* by inositol. Inositol is an inhibitor of phosphatidylserine synthase activity. *J.Biol.Chem* 1988;263:18078–18085. [PubMed: 2848023]
54. Henry SA, Patton-Vogt JL. Genetic regulation of phospholipid metabolism: yeast as a model eukaryote. *Prog.Nucleic Acid Res* 1998;61:133–179.
55. Stryer, L. *Biochemistry*. New York: W.H. Freeman and Company; 1995.
56. Krauss, G. *Biochemistry of signal transduction and regulation*. Germany: Wiley-VCH, Weinheim; 2003.

57. Sreenivas A, Villa-Garcia MJ, Henry SA, Carman GM. Phosphorylation of the yeast phospholipid synthesis regulatory protein Opi1p by protein kinase C. *J.Biol.Chem* 2001;276:29915–29923. [PubMed: 11395523]
58. Sreenivas A, Carman GM. Phosphorylation of the yeast phospholipid synthesis regulatory protein opi1p by protein kinase a. *J.Biol.Chem* 2003;278:20673–20680. [PubMed: 12668681]
59. Karin M, Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. *Curr.Biol* 1995;5:747–757. [PubMed: 7583121]
60. Calkhoven CF, Ab G. Multiple steps in the regulation of transcription-factor level and activity. *Biochem.J* 1996;317:329–342. [PubMed: 8713055]
61. Komeili A, O'Shea EK. Roles of phosphorylation sites in regulating activity of the transcription factor Pho4. *Science* 1999;284:977–980. [PubMed: 10320381]
62. Liu C, Yang Z, Yang J, Xia Z, Ao S. Regulation of the yeast transcriptional factor PHO2 activity by phosphorylation. *J.Biol.Chem* 2000;275:31972–31978. [PubMed: 10884387]
63. Kaffman A, Rank NM, O'Neill EM, Huang LS, O'Shea EK. The receptor Msn5 exports the phosphorylated transcription factor Pho4 out of the nucleus. *Nature* 1998;396:482–486. [PubMed: 9853758]
64. Hung W, Olson KA, Breitkreutz A, Sadowski I. Characterization of the basal and pheromone-stimulated phosphorylation states of Ste12p. *Eur.J.Biochem* 1997;245:241–251. [PubMed: 9151949]
65. Hunter T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. *Cell* 1995;80:225–236. [PubMed: 7834742]
66. Broach JR, Deschenes RJ. The function of RAS genes in *Saccharomyces cerevisiae*. *Adv.Cancer Res* 1990;54:79–139. [PubMed: 2153328]
67. Thevelein JM. Signal Transduction in Yeast. *Yeast* 1994;10:1753–1790. [PubMed: 7747517]
68. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. *Nature* 1984;308:693–698. [PubMed: 6232463]
69. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* 1992;258:607–614. [PubMed: 1411571]
70. Bell RM, Burns DJ. Lipid Activation of protein kinase C. *J.Biol.Chem* 1991;266:4661–4664. [PubMed: 2002013]
71. Levin DE, Fields FO, Kunisawa R, Bishop JM, Thorner J. A candidate protein kinase C gene, *PKC1*, is required for the *S. cerevisiae* cell cycle. *Cell* 1990;62:213–224. [PubMed: 2196995]
72. Mellor H, Parker PJ. The extended protein kinase C superfamily. *Biochem.J* 1998;332(Pt 2):281–292. [PubMed: 9601053]
73. Levin DE, Bartlett-Heubusch E. Mutants in the *S. cerevisiae PKC1* gene display a cell cycle- specific osmotic stability defect. *J.Cell Biol* 1992;116:1221–1229. [PubMed: 1740473]
74. Yang W-L, Carman GM. Phosphorylation and regulation of CTP synthetase from *Saccharomyces cerevisiae* by protein kinase A. *J.Biol.Chem* 1996;271:28777–28783. [PubMed: 8910520]
75. Yang W-L, Bruno MEC, Carman GM. Regulation of yeast CTP synthetase activity by protein kinase C. *J.Biol.Chem* 1996;271:11113–11119. [PubMed: 8626655]
76. Park T-S, Ostrander DB, Pappas A, Carman GM. Identification of Ser⁴²⁴ as the protein kinase A phosphorylation site in CTP synthetase from *Saccharomyces cerevisiae*. *Biochemistry* 1999;38:8839–8848. [PubMed: 10393561]
77. Park T-S, O'Brien DJ, Carman GM. Phosphorylation of CTP synthetase on Ser³⁶, Ser³³⁰, Ser³⁵⁴, and Ser⁴⁵⁴ regulates the levels of CTP and phosphatidylcholine synthesis in *Saccharomyces cerevisiae*. *J.Biol.Chem* 2003;278:20785–20794. [PubMed: 12670958]
78. Choi M-G, Park TS, Carman GM. Phosphorylation of *Saccharomyces cerevisiae* CTP synthetase at Ser⁴²⁴ by protein kinases A and C regulates phosphatidylcholine synthesis by the CDP-choline pathway. *J.Biol.Chem* 2003;278:23610–23616. [PubMed: 12709422]
79. Han G-S, Sreenivas A, Choi MG, Chang YF, Martin SS, Baldwin EP, Carman GM. Expression of human CTP synthetase in *Saccharomyces cerevisiae* reveals phosphorylation by protein kinase A. *J Biol.Chem* 2005;280:38328–38336. [PubMed: 16179339]

80. Chang YF, Martin SS, Baldwin EP, Carman GM. Phosphorylation of human CTP synthetase 1 by protein kinase C: Identification of Ser⁴⁶² and Thr⁴⁵⁵ as major sites of phosphorylation. *J Biol.Chem* 2007;282:17613–17622. [PubMed: 17463002]
81. Choi MG, Carman GM. Phosphorylation of human CTP synthetase 1 by protein kinase A: Identification of Thr455 as a major site of phosphorylation. *J Biol.Chem* 2007;282:5367–5377. [PubMed: 17189248]
82. Thevelein JM, Beullens M. Cyclic AMP and the stimulation of trehalase activity in the yeast *Saccharomyces cerevisiae* by carbon sources, nitrogen sources and inhibitors of protein synthesis. *J.Gen.Microbiol* 1985;131:3199–3209. [PubMed: 3007655]
83. Higgins MJ, Graves PR, Graves LM. Regulation of human cytidine triphosphate synthetase 1 by glycogen synthase kinase 3. *J.Biol.Chem* 2007;282:29493–29503. [PubMed: 17681942]
84. Ambrose MG, Freese SJ, Reinhold MS, Warner TG, Vann WF. ¹³C NMR investigation of the anomeric specificity of CMP-N-acetylneuraminic acid synthetase from *Escherichia coli*. *Biochemistry* 1992;31:775–780. [PubMed: 1731934]
85. Kelsall A, Meuth M. Direct selection of chinese hamster ovary strains deficient in CTP synthetase activity. *Somat.Cell Mol.Genet* 1988;14:149–154. [PubMed: 3162335]
86. Robert de Saint Vincent B, Buttin G. Studies on 1-b-D-arabinofuranosylcytosine-resistant mutants of chinese hamster fibroblasts. IV. Altered regulation of CTP synthetase generates arabinosylcytosine and thymidine resistance. *Biochim.Biophys.Acta* 1980;610:352–359.
87. Trudel M, van Genechten T, Meuth M. Biochemical characterization of the hamster Thy mutator gene and its revertants. *J.Biol.Chem* 1984;259:2355–2359. [PubMed: 6698969]
88. Meuth M, Goncalves O, Thom P. A selection system specific for the thy mutator phenotype. *Somat.Cell Genet* 1982;8:423–432. [PubMed: 7123450]
89. Aronow B, Watts T, Lassetter J, Washtien W, Ullman B. Biochemical phenotype of 5-fluorouracil-resistant murine T-lymphoblasts with genetically altered CTP synthetase activity. *J.Biol.Chem* 1984;259:9035–9043. [PubMed: 6611336]
90. Kaufman ER. Altered CTP synthetase activity confers resistance to 5-bromodeoxyuridine toxicity and mutagenesis. *Muta.Res* 1986;161:19–27.
91. Chu EHY, McLaren JD, Li I-C, Lamb B. Pleiotropic mutants of chinese hamster cells with altered cytidine 5'-triphosphate synthetase. *Biochem.Genet* 1984;22:701–715. [PubMed: 6497832]
92. Aronow B, Ullman B. *In situ* regulation of mammalian CTP synthetase by allosteric inhibition. *J.Biol.Chem* 1987;262:5106–5112. [PubMed: 2435724]
93. Hatch GM, McClarty G. Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5'-triphosphate. *J.Biol.Chem* 1996;271:25810–25816. [PubMed: 8824210]
94. Verschuur AC, van Gennip AH, Muller EJ, Voute PA, Van Kuilenburg AB. Increased activity of cytidine triphosphate synthetase in pediatric acute lymphoblastic leukemia. *Adv Exp Med Biol* 1998;431:667–671. [PubMed: 9598149]
95. Whelan J, Smith T, Phear G, Rohatiner A, Lister A, Meuth M. Resistance to cytosine arabinoside in acute leukemia: the significance of mutations in CTP synthetase. *Leukemia* 1994;8:264–265. [PubMed: 8309250]
96. van den Berg AA, van Lenthe H, Busch S, de Korte D, Roos D, van Kuilenburg ABP, van Gennip AH. Evidence for transformed-related increase in CTP synthetase activity *in situ* in human lymphoblastic leukemia. *Eur.J.Biochem* 1993;216:161–167. [PubMed: 8365402]
97. van den Berg AA, van Lenthe H, Kipp JB, de Korte D, Van Kuilenburg AB, van Gennip AH. Cytidine triphosphate (CTP) synthetase activity during cell cycle progression in normal and malignant T-lymphocytic cells. *Eur J Cancer* 1995;31A:108–112. [PubMed: 7695960]
98. Kizaki H, Williams JC, Morris HP, Weber G. Increased cytidine 5'-triphosphate synthetase activity in rat and human tumors. *Cancer Res* 1980;40:3921–3927. [PubMed: 7471043]
99. Weber G, Lui MS, Takeda E, Denton JE. Enzymology of human colon tumors. *Life Sci* 1980;27:793–799. [PubMed: 7412505]
100. Weber G, Olah E, Lui MS, Tzeng D. Biochemical programs and enzyme-pattern-targeted chemotherapy in cancer cells. *Adv.Enzyme Regul* 1979;17:1–21. [PubMed: 757309]

101. Verschuur AC, van Gennip AH, Brinkman J, Voute PA, Van Kuilenburg AB. Cyclopentenyl cytosine induces apoptosis and secondary necrosis in a T-lymphoblastic leukemic cell-line. *Adv.Exp.Med.Biol* 2000;486:319–325. [PubMed: 11783508]
102. Verschuur AC, Brinkman J, van Gennip AH, Leen R, Vet RJ, Evers LM, Voute PA, Van Kuilenburg AB. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line. *Leuk.Res* 2001;25:891–900. [PubMed: 11532523]
103. Williams JC, Kizaki H, Weber G, Morris HP. Increased CTP synthetase activity in cancer cells. *Nature* 1978;271:71–72. [PubMed: 203856]
104. Hofer A, Steverding D, Chabes A, Brun R, Thelander L. *Trypanosoma brucei* CTP synthetase: a target for the treatment of African sleeping sickness. *Proc.Natl.Acad.Sci.U.S.A* 2001;98:6412–6416. [PubMed: 11353848]
105. Hendriks EF, O'Sullivan WJ, Stewart TS. Molecular cloning and characterization of the *Plasmodium falciparum* cytidine triphosphate synthetase gene. *Biochim.Biophys.Acta* 1998;1399:213–218. [PubMed: 9765599]
106. Hacker S, Sohlenkamp C, Aktas M, Geiger O, Narberhaus F. Multiple phospholipids N-methyltransferases with distinct substrate specificities are encoded in *Bradyrhizobium japonicum*. *J.Bacteriol* 2008;190:571–580. [PubMed: 17993534]
107. Wylie JL, Berry JD, McClarty G. *Chlamydia trachomatis* CTP synthetase: molecular characterization and developmental regulation of expression. *Mol.Microbiol* 1996;22:631–642. [PubMed: 8951811]
108. Politi PM, Xie F, Dahut W, Ford H Jr, Kelley JA, Bastian A, Setser A, Allegra CJ, Chen AP, Hamilton JM. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. *Cancer Chemother.Pharmacol* 1995;36:513–523. [PubMed: 7554044]
109. Verschuur AC, van Gennip AH, Leen R, Muller EJ, Elzinga L, Voute PA, Van Kuilenburg AB. Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. *Eur.J.Cancer* 2000;36:627–635. [PubMed: 10738128]
110. Gao WY, Johns DG, Mitsuya H. Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine. *Nucleosides Nucleotides* 2000;19:371–377.
111. Moriconi WJ, Slavik M, Taylor S. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. *Invest New Drugs* 1986;4:67–84. [PubMed: 2422137]

Fig. 1. Reaction catalyzed by CTP synthetase

The figure shows the structures of UTP and CTP, and the reaction catalyzed by CTP synthetase.

Fig. 2. The role of CTP synthetase in the synthesis of the major phospholipids in *S. cerevisiae*
 The pathways shown for the synthesis of phospholipids include the relevant steps discussed in this review. A more comprehensive description of the phospholipid biosynthetic pathways in *S. cerevisiae* may be found in references [7,54]. The abbreviations used are: PA, phosphatidate; Etn, ethanolamine; P-Etn, phosphoethanolamine; CDP-DAG, CDP-diacylglycerol; CDP-Etn, CDP-ethanolamine; CDP-Cho, CDP-choline; PI, phosphatidylinositol; PG, phosphatidylglycerol; PS, phosphatidylserine; PE, phosphatidylethanolamine, PC, phosphatidylcholine; SLs, sphingolipids; PIPs, polyphosphoinositides. The Kennedy and CDP-DAG pathways are differentiated by color.

Fig. 3. Domain structure of *URA7*-encoded CTP synthetase

The diagram shows the approximate positions of the CTP synthetase domain and the glutamine amide transfer domain in the CTP synthetase sequence. The sites involved in CTP product inhibition and phosphorylations by protein kinases A and C are indicated.

Fig. 4. Model for the role of phosphorylation in the nucleotide-dependent tetramerization and activation of the *URA7*-encoded CTP synthetase

The *square* represents the dephosphorylated CTP synthetase subunit, and the *circle* containing the letter *P* represents the phosphorylated enzyme subunit. The model is adapted from reference [23].